Bluejay Diagnostics, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
Bluejay Diagnostics, Inc. (BJDX) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of -0.05% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-06.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2026-03-06
- Bluejay Diagnostics, Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2025 was -0.05%.
- Bluejay Diagnostics, Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2024 was -0.08%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month |
|---|---|
| 2025-12-31 | -0.05% 10-K · filed 2026-03-06 |
| 2024-12-31 | -0.08% 10-K · filed 2026-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| AETHLON MEDICAL INC (AEMD) | United States | $0.005B | |
| INTELLIGENT BIO SOLUTIONS INC. (INBS) | United States | $0.005B | |
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| Vivos Therapeutics, Inc. (VVOS) | United States | $0.003B | -0.26 |
| Sonoma Pharmaceuticals, Inc. (SNOA) | United States | $0.006B | -2.59 |
| NEXGEL, INC. (NXGL) | United States | $0.002B | |
| INVO Fertility, Inc. (IVF) | United States | $0.002B | -0.71 |